Using our technology, we have managed to isolate phenolic and alkaloids from plants. We have launched anti-aging cream and liver tonic syrup (Swaliv) in India. In addition, we are bringing two more products in market shortly.
We have few products in Phase 0 and looking to collaborate pharma company to take it further. We are open to out licence the skin care and Nutraceuticals.
Natural products have been the source of most of the active ingredients of medicines. Natural products possess enormous structural and chemical diversity that cannot be matched by any synthetic libraries of small molecules and continue to inspire novel discoveries in chemistry, biology, and medicine. More than 80% of drug substances were natural products or inspired by a natural compound. They are evolutionarily optimized as drug-like molecules and remain the best sources of drugs and drug leads (Newman and Cragg, 2012).
Last 30 years of NDA have found that about 64% of drugs are still of secondary metabolites, and that is when pharmaceutical industry increased HTS and combinatory chemistry. This gives the opportunity to target small molecules from plants as drug leads in different disease.
Synthetic lethality, namely, the process by which defects in two different genes or pathways together result in cell death while defects in one of the two different genes or pathways do not affect viability. This attractive new therapeutic strategy based on the principle of synthetic lethality relies on the frequent defects in the DNA damage response observed in cancer.
DNA damage response pathways may be activated to allow cancer cells to survive in the presence of genotoxic stress. Because this strategy targets the cancer-specific aberrations in the DNA damage response, it will cause few or no toxicities on normal cells.
Principle of synthetic lethality- DNA damage is often processed by multiple DNA repair pathways. Pathways A and B are both intact in normal cells, whereas pathway A is defective in cancer cells.(a) In the absence of the pathway B inhibitor, cancer cells can survive, because the defect in pathway A is compensated by the alternative pathway B. (b) When the cells are treated with the pathway B inhibitor, both pathways will be blocked in cancer cells, which will result in cell death. However, normal cells will not be affected, because inhibition of pathway B will be compensated by pathway A
Swalife Technology is divided in four stages-
Stage 1: Based on the literature plants are selected and authentic plants are grown in farm with the farmers, which are collaborated with company. The plant samples are collected and then pass through the extraction/ fraction methods. These samples are then screen using phenotypic high content screening (HCS) assays. The aim of HCS is to find the bioactive and toxic extracts.
Stage 2: The bioactive and toxic extracts are then fractionated with liquid-liquid fractionation method. The fraction prepared with this method are then screen with HCS assays. The bioactive fractions are used in nutraceuticals and skin care products. While the toxic fractions are moved into stage 3.
Stage 3: The toxic fractions are de-replicated with LC-MS/MS and Q-tof. The de-replication helps to get the predicated structure of the compounds in the fractions. The structures are then used in molecular docking to modify and identify the more bioactive compound on targeted proteins from DNA damage response. These high active and modified compounds are synthesised or semi-synthesized. These compounds are then transfer to stage 4 of the technology.
Stage 4: Compounds from stage 3 goes through HCS assays using embryo of Zebrafish. Compound/s selected from Zebrafish are confirm with animal models. Positive results from animal studies are moved in Phase 0 studies.
© | SwaLife Biotech | All rights reserved. | Web Presence By Sujatha Tech Solutions